A Study to Evaluate a Study Drug, DCB-BO1202, for Alleviating Liver Fibrosis in Liver Cancer Patients
Status:
Withdrawn
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether an investigational drug DCB-BO1202 is
effective and safe in the treatment of liver fibrosis in HBV patients having experienced
intermediate stage hepatocellular carcinoma (HCC)